Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP287728.RAVb7FL3J3Q43Uvq0KurI6I4Rlhc-EfzDIBwrkDFIhaOE130_assertion description "[When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP287728.RAVb7FL3J3Q43Uvq0KurI6I4Rlhc-EfzDIBwrkDFIhaOE130_provenance.
• NP776076.RAM4F6qxCBPzqUdOyGb2Chjuwnsv4gdwqYDvv-r3dNf9U130_assertion description "[When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP776076.RAM4F6qxCBPzqUdOyGb2Chjuwnsv4gdwqYDvv-r3dNf9U130_provenance.
• NP363795.RAGpNdOLCrYo2ldq1scf0_cG-p1bT7R21P6uGUGC99N-g130_assertion description "[When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP363795.RAGpNdOLCrYo2ldq1scf0_cG-p1bT7R21P6uGUGC99N-g130_provenance.
• NP684788.RA7UbHn051f81xE3p3fARC86sehutzH_ecHwahM37tlIk130_assertion description "[When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP684788.RA7UbHn051f81xE3p3fARC86sehutzH_ecHwahM37tlIk130_provenance.
• NP400191.RA5wuBmQSB6GTR1D5l1Rm42ame8joHQ6U4FhZDF4HuTsc130_assertion description "[When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP400191.RA5wuBmQSB6GTR1D5l1Rm42ame8joHQ6U4FhZDF4HuTsc130_provenance.
• assertion description "[When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP1076273.RAcXHhIYseHLtwvQhf8RxgfsgRoViv-63Rj-AEV6Wzm8k130_assertion description "[When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1076273.RAcXHhIYseHLtwvQhf8RxgfsgRoViv-63Rj-AEV6Wzm8k130_provenance.
• NP399182.RANvY2OjbsI2W5kFkKN0CbkgjSA6P4cygfgbHzPkolRUE130_assertion description "[When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP399182.RANvY2OjbsI2W5kFkKN0CbkgjSA6P4cygfgbHzPkolRUE130_provenance.
• NP1076276.RAHFulaJJSuBUd4qxqzw7yQfS1aZXA8MH7_S1zk0cRaNg130_assertion description "[When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1076276.RAHFulaJJSuBUd4qxqzw7yQfS1aZXA8MH7_S1zk0cRaNg130_provenance.
• NP400605.RAnqS96XBpmfnMzwCCuCy-J4mKMMJqIRFkkKpjUSobr-g130_assertion description "[When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP400605.RAnqS96XBpmfnMzwCCuCy-J4mKMMJqIRFkkKpjUSobr-g130_provenance.
• NP399045.RAjs7-nL0MkxiJojPtgjuIM7r9rJj5Xd_mipwPFWNBwWQ130_assertion description "[When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP399045.RAjs7-nL0MkxiJojPtgjuIM7r9rJj5Xd_mipwPFWNBwWQ130_provenance.
• NP1076274.RAtWh-Rmp5CZwLfmu0NMeUDZp8m3XOn4tfBhCq0kVu9IM130_assertion description "[When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1076274.RAtWh-Rmp5CZwLfmu0NMeUDZp8m3XOn4tfBhCq0kVu9IM130_provenance.
• NP1076275.RAkEDJe4uDlUpHD4NeT7K446QI4F23fRnAXwU8usIGGxU130_assertion description "[When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1076275.RAkEDJe4uDlUpHD4NeT7K446QI4F23fRnAXwU8usIGGxU130_provenance.